Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Michael Deininger
Medical College of Wisconsin, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Pfizer
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Committee's Finding of Conflict:
The investigator has a significant financial interest with Pfizer, who manufactures drugs that are being evaluated in the study.
Stopping Tyrosine Kinase Inhibitors in CML Patients (Stop-TKIs)
Tyrosine kinase inhibitors (TKIs) have dramatically improved the survival of patients with chronic myeloid leukemia (CML), leading to an unforeseen increase in prevalence. The current recommendation is to continue therapy indefinitely, despite high costs and significant side effects that decrease patients' health-related quality of life. The Stopping Tyrosine Kinase Inhibitors in CML Patients (Stop TKIs) study will discontinue TKI therapy in 170 willing and eligible CML patients and monitor them closely for 3 years to characterize the patient factors associated with CML recurrence, describe patient-reported health status changes after TKI discontinuation, and explore patient decision making regarding discontinuation with monitoring.
Filed on July 10, 2018.
Tell us what you know about Michael Deininger's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Michael Deininger”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Michael Deininger | University of Utah | Conflict of Interest | Bristol-Myers Squibb | $5,000-9,999 |
| Michael Deininger | University of Utah | Conflict of Interest | Pfizer | $5,000-9,999 |
| Michael Deininger | University of Utah | Conflict of Interest | Novartis | $10,000-19,999 |
| Michael Deininger | University of Utah | Conflict of Interest | Pfizer | $10,000-19,999 |
| Michael Deininger | University of Utah | Conflict of Interest | Pfizer | $5,000-9,999 |
| Michael Deininger | University of Utah | Conflict of Interest | Ariad | $5,000-9,999 |
| Michael Deininger | University of Utah | Conflict of Interest | Pfizer | $10,000-19,999 |
| Michael Deininger | University of Utah | Conflict of Interest | Pfizer | $10,000-19,999 |
| Michael Deininger | University of Utah | Conflict of Interest | Pfizer | $10,000-19,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.